Regenerative Stem Cell Therapy for Stroke in Europe 1-RESSTORE1

Stroke is the second leading cause of death in the world population. When not fatal, stroke often results in disability, and secondary health problems affecting not only patients but also their families. Building on emerging preclinical and pilot clinical evidences, RESSTORE will focus on the clinical assessment of regenerative cell therapy to improve stroke recovery and patients quality of life.

NCT Number	NCT03570450
Lead Sponsor	University Hospital, Grenoble Collaborators: Horizon 2020 - European Commission, University Grenoble Alps, Servicio Madrileño de Salud, Madrid, Spain, St. Anne's University Hospital Brno, Czech Republic, Andaluz Health Service, University of Glasgow, University of Eastern Finland, Etablissement Français du Sang, Tampere University, Histocell SL, Spain, Oy Medfiles Ltd, Institut National de la Santé Et de la Recherche Médicale, France, Hospices Civils de Lyon, Association Groupe ESSEC, NOVADISCOVERY SAS, France, Finovatis, Centre Hospitalier Universitaire de Besancon, Assistance Publique - Hôpitaux de Paris, University Hospital, Toulouse, University Hospital, Bordeaux, University Hospital, Caen, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Servicio de Salud de Castilla La Mancha, Albacete, Spain, Servicio Gallego de Salud, Pirkanmaa Hospital District, Tampere, Finland, Hospital Vall d'Hebron, Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta, CH Sainte-Anne, Paris, France
Conditions	Stroke
Enrollment	95 participants
Start Date	2018-06-02
Primary Completion	2025-07-01 (estimated)
Study Completion	2027-07-01 (estimated)
Updated on ClinicalTrials.gov	2023-07-27